Remibrutinib
Remibrutinib is an oral small molecule medication that inhibits Bruton's tyrosine kinase (BTK), an enzyme critical for the function and survival of certain immune cells including B cells, mast cells, and macrophages. As a BTK inhibitor, it is being investigated for the treatment of autoimmune and inflammatory conditions where these immune cells play a role in disease progression. By blocking BTK signaling, remibrutinib reduces the activation and inflammatory responses driven by these cell types.
Remibrutinib is an oral BTK inhibitor being developed for autoimmune and inflammatory conditions that works by blocking signaling in key immune cells.
Key facts at a glance
- ATC
- L04AA60
- RxNorm
- 2724365
- Generic
- Remibrutinib
- Class
- atc-l04
- Brands
- Rhapsido
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Remibrutinib is being investigated for various autoimmune and inflammatory conditions, including chronic spontaneous urticaria, multiple sclerosis, and other diseases where B-cell and mast cell activation contribute to pathology. Clinical trials are ongoing to evaluate its efficacy and safety in these indications.
Remibrutinib selectively inhibits Bruton's tyrosine kinase (BTK), an intracellular enzyme expressed in mast cells, basophils, B cells, macrophages, and thrombocytes. BTK plays a crucial role in signaling pathways downstream of various immune receptors, including Fc epsilon receptors. By blocking BTK activity, remibrutinib disrupts the activation and inflammatory responses of these immune cells.
As an oral medication, remibrutinib offers convenient dosing compared to injectable therapies. Common side effects of BTK inhibitors may include gastrointestinal symptoms, infections, and hematologic changes. Patients should be monitored for signs of infection and liver function abnormalities. The medication is still under investigation for several indications and regulatory approvals vary by country.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy